United StatesHealth

OmniAb (NASDAQ:OABI) raised its year-end 2026 cash and cash equivalents guidance to $49 million–$53 million from $37 million–$41 million previously.

OmniAb (NASDAQ:OABI) signed a global collaboration and license agreement with Eli Lilly (NYSE:LLY) covering a new ion channel drug discovery program.

NRx Pharmaceuticals (NASDAQ:NRXP) reported a first-half 2026 net loss of $18 million versus $23.1 million a year earlier, while cash increased to $26.7 million.

EyePoint (NASDAQ:EYPT) said DURAVYU 2.7mg missed LUGANO’s primary BCVA endpoint against 2mg aflibercept in the full Phase 3 dataset.

InspireMD (NASDAQ:NSPR) reported Q2 2026 revenue of $1.77 million, down 0.4% year-over-year, while its net loss widened to $14.3 million.

Lifeward (NASDAQ:LFWD) reported Q2 2026 revenue of $6.62 million, up 16% year-over-year, while adjusted loss was $1.46 per share.

Sinovac Biotech (NASDAQ:SVA) reported first-half 2026 sales of $147.1 million, up from $130.3 million, while net loss attributable to common shareholders widened to $60.2 million.

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said ENHERTU significantly improved progression-free survival versus standard first-line treatment in the Phase III DESTINY-Lung04 lung cancer trial.

IM Cannabis (NASDAQ:IMCC) executed a definitive agreement on August 16, 2026, to sell all shares of I.M.C. Holdings to Slil.com Holding to clear up to C$9.4 million in liabilities.

Zai Lab (NASDAQ:ZLAB) and argenx (NASDAQ:ARGX) reported that VYVGART Hytrulo met the Phase 3 ALKIVIA primary endpoint with a 15.4-point TIS advantage over placebo at Week 52.

Centene (NYSE:CNC) named Chris Neczypor as its next CFO from January 1, 2027, while reaffirming 2026 adjusted diluted EPS guidance above $4.80.

HUTCHMED (NASDAQ:HCM) reported that ORPATHYS plus TAGRISSO significantly improved progression-free and overall survival versus platinum-based chemotherapy in its 338-patient Phase 3 SAFFRON trial.